AU Patent

AU2012254935B2 — Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders

Assigned to Archemix LLC · Expires 2014-05-29 · 12y expired

What this patent protects

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders. -e- C5a,ARC1905 100- A C5a,ARC127 0 C3a,ARC1905 z * C3a,ARC127 -50 10 100 1000 [APTAMER] nM Fig.67

USPTO Abstract

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders. -e- C5a,ARC1905 100- A C5a,ARC127 0 C3a,ARC1905 z * C3a,ARC127 -50 10 100 1000 [APTAMER] nM Fig.67

Drugs covered by this patent

avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM)

Patent Metadata

Patent number: AU2012254935B2
Jurisdiction: AU
Classification: —
Expires: 2014-05-29
Drug substance claim: No
Drug product claim: No
Assignee: Archemix LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.